Cibc World Market Inc. Has $9.51 Million Stock Holdings in Becton, Dickinson and Company $BDX

Cibc World Market Inc. raised its holdings in Becton, Dickinson and Company (NYSE:BDX) by 938.6% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 62,834 shares of the medical instruments supplier’s stock after buying an additional 56,784 shares during the quarter. Cibc World Market Inc.’s holdings in Becton, Dickinson and Company were worth $9,509,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Brighton Jones LLC grew its holdings in shares of Becton, Dickinson and Company by 98.2% during the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after purchasing an additional 877 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Becton, Dickinson and Company by 4.4% in the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 627,900 shares of the medical instruments supplier’s stock valued at $122,403,000 after buying an additional 26,671 shares in the last quarter. Cooke & Bieler LP raised its stake in shares of Becton, Dickinson and Company by 27.2% in the 4th quarter. Cooke & Bieler LP now owns 1,126,471 shares of the medical instruments supplier’s stock valued at $218,614,000 after buying an additional 240,673 shares in the last quarter. Northside Capital Management LLC lifted its holdings in shares of Becton, Dickinson and Company by 18.3% during the 2nd quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock worth $9,280,000 after acquiring an additional 9,494 shares during the period. Finally, Wealthfront Advisers LLC acquired a new stake in shares of Becton, Dickinson and Company during the 2nd quarter valued at about $2,567,000. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Price Performance

Shares of BDX stock opened at $190.58 on Tuesday. The stock has a 50-day moving average price of $162.48 and a 200 day moving average price of $160.73. The company has a quick ratio of 0.51, a current ratio of 0.87 and a debt-to-equity ratio of 0.55. The firm has a market cap of $52.51 billion, a price-to-earnings ratio of 57.40, a PEG ratio of 13.53 and a beta of 0.19. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $193.07.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.09. The firm had revenue of $4.98 billion during the quarter, compared to analysts’ expectations of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%.The company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period in the previous year, the business posted $3.68 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Research analysts expect that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Investors of record on Wednesday, September 9th will be issued a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 126.51%.

Insider Activity at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 1,100 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president directly owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. This trade represents a 7.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 4,152 shares of Becton, Dickinson and Company stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $185.00, for a total transaction of $768,120.00. Following the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $20,380,155. This represents a 3.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 11,704 shares of company stock worth $1,963,618 over the last ninety days. Company insiders own 0.40% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on BDX shares. The Goldman Sachs Group dropped their target price on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research report on Wednesday, May 27th. TD Cowen lifted their target price on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Wells Fargo & Company boosted their target price on Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a report on Friday, August 7th. Jefferies Financial Group restated a “buy” rating and set a $210.00 price target on shares of Becton, Dickinson and Company in a research report on Thursday, August 6th. Finally, Piper Sandler lifted their price objective on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a “neutral” rating in a research report on Friday, August 7th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Becton, Dickinson and Company has a consensus rating of “Hold” and a consensus target price of $185.67.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.